De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the molecular mechanisms responsible for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Magistroni, Vera, Mauri, Mario, D’Aliberti, Deborah, Mezzatesta, Caterina, Crespiatico, Ilaria, Nava, Miriam, Fontana, Diletta, Sharma, Nitesh, Parker, Wendy, Schreiber, Andreas, Yeung, David, Pirola, Alessandra, Readelli, Sara, Massimino, Luca, Wang, Paul, Khandelwal, Praveen, Citterio, Stefania, Viltadi, Michela, Bombelli, Silvia, Rigolio, Roberta, Perego, Roberto, Boultwood, Jacqueline, Morotti, Alessandro, Saglio, Giuseppe, Kim, Dong-Wook, Branford, Susan, Gambacorti-Passerini, Carlo, Piazza, Rocco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717574/
https://www.ncbi.nlm.nih.gov/pubmed/30819912
http://dx.doi.org/10.3324/haematol.2017.179937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717574/
https://www.ncbi.nlm.nih.gov/pubmed/30819912
http://dx.doi.org/10.3324/haematol.2017.179937

Ejemplares similares